Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis

Table 1 Clinical characteristics of the included patients n (%)

Variables	Peritonitis group (n = 61)	No peritonitis group (n = 59)	P value
Age (yr), [median (range)]	51 (27-79)	49 (24-77)	0.653
Sex (male)	55 (52.9)	81 (56.6)	0.558
Height (cm)	162.09 ± 6.94	163.21 ± 8.45	0.435
Bwt (kg)	57.68 ± 8.41	59.49 ± 11.24	0.332
BMI [m/(kg)2]	21.98 ± 2.73	22.26 ± 3.48	0.628
Cause of ESRD
Glomerulonephritis	19 (31.1)	20 (33.9)	0.153
DM	21 (34.4)	12 (20.3)
HTN	5 (8.2)	1 (1.7)
Polycystic kidney disease	1 (1.6)	2 (3.4)
Unknown/idiopathic	11 (18.0)	17 (28.8)
Other cause	4 (6.6)	7 (11.9)
HTN	50 (82.0)	53 (89.8)	0.217
DM	23 (37.7)	17 (28.8)	0.302
Diverticulosis	1 (2.3)	3 (6.7)	0.616
PD modality (CAPD)	51 (83.6)	47 (79.7)	0.577
Initial serum Albumin (mg/dL)	3.51 ± 0.47	3.60 ± 0.48	0.336
Peritonitis free time (d),
[median (range)]	762 (31-3918)	1302 (100-4234)	0.070

Data presented as mean ± SD, unless otherwise stated. Bwt: Body weight; BMI: Body mass index; ESRD: End stage renal disease; DM: Diabetes mellitus; HTN: Hypertension; LC: Liver cirrhosis; PD: Peritoneal dialysis; CAPD: Continuous ambulatory peritoneal dialysis.